QIAGEN Receives Several Conditional, Non-binding Indications of Interest, Enters Into Discussions to Explore Potential Strate...
15 Novembro 2019 - 5:22PM
Business Wire
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA)
(“QIAGEN” or the “Company”) announces it has begun a review of
potential strategic alternatives after receiving several
conditional, non-binding indications of interest for the
acquisition of all issued and outstanding shares of the
Company.
The Supervisory Board and the Management Board of QIAGEN, in
accordance with their fiduciary duties and as part of the review of
potential strategic alternatives, are starting discussions with
interested parties. These discussions aim to explore potential
strategic alternatives that could provide greater value creation
opportunities than the already strong stand-alone growth prospects
for the Company, taking into consideration the interests of
QIAGEN’s stakeholders including its shareholders.
There is no guarantee or certainty that these discussions will
lead to a recommended firm offer to all shareholders of the
Company.
QIAGEN remains committed to serving its more than 500,000
customers worldwide with a portfolio of Sample to Insight solutions
focused on exciting areas of molecular testing, executing on
strategies for growth while continuing to exercise financial
discipline.
Further announcements will be made if and when required.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare) and
Life Sciences (academia, pharma R&D and industrial
applications, primarily forensics). As of September 30, 2019,
QIAGEN employed approximately 5,200 people in over 35 locations
worldwide. Further information can be found at http://www.qiagen.com.
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. Such
statements include statements with respect to the Company's
strategic plans and exploration of strategic alternatives. Words
such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,'
'seeks,' 'estimates,' and similar expressions are intended to
identify forward-looking statements. All statements contained in
this announcement that do not relate to matters of historical fact
should be considered forward-looking statements, including with
respect to the status of any discussions with potential
counterparties, the possibility of completing a transaction, and
any outcome of a strategic alternative evaluation process. These
statements are neither promises nor guarantees, but involve known
and unknown risks, uncertainties and other important factors that
may cause our actual results, performance or achievements to be
materially different from our expectations expressed or implied by
the forward-looking statements, including, but not limited to, the
general uncertainty around future plans for the Company.
Additionally, the Company’s exploration of strategic alternatives
represents a potential material change in business strategy, which
the Company may not be able to execute effectively, on any specific
timeline, or at all, and its failure to do so may impact the price
and volatility of the Company’s publicly traded shares. These risks
and uncertainties could cause actual results to differ materially
from those indicated by the forward-looking statements made in this
announcement. Such forward-looking statements also are subject to
risks and uncertainties related to the Company’s business,
including but not limited to, risks associated with management of
growth and international operations (including the effects of
currency fluctuations, regulatory processes and dependence on
logistics); variability of operating results and allocations
between customer classes; the commercial development of markets for
our products to customers in academia, pharma, applied testing and
molecular diagnostics; changing relationships with customers,
suppliers and strategic partners; competition; rapid or unexpected
changes in technologies; fluctuations in demand for QIAGEN's
products (including fluctuations due to general economic
conditions, the level and timing of customers' funding, budgets and
other factors); our ability to obtain regulatory approval of our
products; difficulties in successfully adapting QIAGEN's products
to integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses; and the other factors discussed under
the heading “Risk Factors” contained in Item 3 of our most recent
Annual Report on Form 20-F. For further information, please refer
to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission (SEC).
Any such forward-looking statements represent management's
estimates as of the date of this announcement. While we may elect
to update such forward-looking statements at some point in the
future, we disclaim any obligation to do so, even if subsequent
events cause our views to change, except as required by law or by
any appropriate regulatory authority. These forward-looking
statements should not be relied upon as representing our views as
of any date subsequent to the date of this announcement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191115005474/en/
John Gilardi Vice President, Head of Corporate Communications
and Investor Relations +49 2103 29 11711 and +1 240 686 2222
john.gilardi@qiagen.com Phoebe Loh Associate Director Investor
Relations +49 2103 29 11457 phoebe.loh@qiagen.com Dr. Thomas
Theuringer Senior Director Public Relations and Digital
Communications +49 2103 29 11826 and +1 240 686 7425
thomas.theuringer@qiagen.com Robert Reitze Senior Manager Public
Relations +49 2103 29 11676 robert.reitze@qiagen.com
www.twitter.com/qiagen www.facebook.com/QIAGEN
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024